Cladribine (2-CDA) given as subcutaneous bolus injections is active in pretreated Waldenstrom's macroglobulinaemia

British Journal of Haematology

Volumn 99, Issue 2, 1997, Pages 358-363

  Betticher, D C ^a,f   Hsu Schmitz, S F ^b   Ratschiller, D ^a   Von Rohr, A ^a   Egger, T ^a   Pugin, P ^c   Stalder, M ^d   Hess, U ^e   Fey, M F ^a   Cerny, T ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b SIAK Coordinating Center   (Switzerland)

^c Division of Oncology   (Switzerland)

^d Institut Central des Hopitaux Valaisans   (Switzerland)

^e Kantonsspital St Gallen Division of Oncology Haematology   (Switzerland)

^f UNIVERSITY OF BERN   (Switzerland)

Author keywords

2 chlorodeoxyadenosine; Cladribine; Subcutaneous administration; Treatment; Waldenstrom's macroglobulinaemia

Indexed keywords

ALPHA INTERFERON; ANTHRACYCLINE ANTIBIOTIC AGENT; BLEOMYCIN; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; ETOPOSIDE; FLUDARABINE PHOSPHATE; IFOSFAMIDE; MELPHALAN; METHOTREXATE; STEROID; VINCRISTINE;

ADULT; AGED; ARTICLE; BOLUS INJECTION; BONE MARROW TOXICITY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG BIOAVAILABILITY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MULTICENTER STUDY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; REMISSION; SEPTICEMIA; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; TREATMENT FAILURE; VIRUS ENCEPHALITIS; WALDENSTROEM MACROGLOBULINEMIA;

EID: 9844262268     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1997.3923206.x     Document Type: Article

References (25)

1. Clamon, G.H., Corder, M.P. & Burns, C.P. (1980) Successful doxorubicin therapy of primary macroglobulinemia resistant to alkylating agents. American Journal of Hematology, 9, 221-223.
2. Delannoy, A., Ferrant, A., Martiat, P., Bosly, A., Zenebergh, A. & Michaux, J.L. (1994) 2-Chlorodeoxyadenosine therapy in Waldenström's macroglobulinaemia. Nouvelle Revue Française d'Hématologie, 36, 317-320.
3. Dimopoulos, M.A. & Alexanian, R. (1994) Waldenström's macroglobulinemia. Blood, 83, 1452-1459.
4. Dimopoulos, M.A., Kantarjian, H.M., Estey, E.H. & Alexanian, R. (1992) 2-Chlorodeoxyadenosine in the treatment of multiple myeloma. Blood, 80, 1626.
5. Dimopoulos, M.A., Kantarjian, H., Estey, E., O'Brien, S., Delasalle, K., Keating, M.J., Freireich, E.J. & Alexanian, R. (1993a) Treatment of Waldenström macroglobulinemia with 2-chlorodeoxyadenosine. Annals of Internal Medicine, 118, 195-198.
6. Dimopoulos, M.A., Kantarjian, H., Weber, D., Weber, D., O'Brien, S., Estey, E., Desalle, K., Rose, E., Cabanillas, F., Keating, M. & Alexanian, R. (1994) Primary therapy of Waldenström's macroglobulinemia with 2-chlorodeoxyadenosine. Journal of Clinical Oncology, 12, 2694-2698.
7. Dimopoulos, M.A., O'Brien, S., Kantarjian, H., Pierce, S., Delasalle, K., Barlogie, B., Alexanian, R. & Keating, M.J. (1993b) Fludarabine therapy in Waldenström's macroglobulinemia. American Journal of Medicine, 95, 49-52.
8. Dimopoulos, M.A., Weber, D., Delasalle, K.B., Keating, M. & Alexanian, R. (1995) Treatment of Waldenström's macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: identification of prognostic factors. Annals of Oncology, 6, 49-52.
9. Facon, T., Brouillard, M., Duhamel, A., Morel, P., Simon, M., Jouet, J.P., Bauters, F. & Fenaux, P. (1993) Prognostic factors in Waldenström's macroglobulinemia: a report of 167 cases. Journal of Clinical Oncology, 11, 1553-1558.
10. Guchelaar, H.J., Richel, D.J. & Schaffsma, M.R. (1994) Clinical and toxicological aspects of the antineoplastic drug cladribine: a review. Annals of Hematology, 69, 223-2230.
11. Jane, S.M. & Salem, H.H. (1988) Treatment of resistant Waldenström's macroglobulinemia with high dose glucocorticosteroids. Australian and New Zealand Journal of Medicine, 18, 77-78.
12. Juliusson, G., Heldal, D., Hippe, E., Hedenus, M., Malm, C., Wallman, K., Stolt, C.M., Evensen, S.A., Albertioni, F., Tjonnfjord, G., Likie, R. & Liliemark, J. (1995) Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia. Journal of Clinical Oncology, 13, 989-995.
13. Kantarjian, H.M., Alexanian, R., Koller, C.A., Kurzrock, R. & Keating, M.J. (1990) Fludarabine therapy in macroglobulinemic lymphoma. Blood, 75, 1928-1931.
14. Liliemark, J., Albertioni, F., Hassan, M. & Juliusson, G. (1992) On the bioavailibility of oral and subcutaneous 2-chloro-2′-deoxyadenosine in humans: alternative routes of administration. Journal of Clinical Oncology, 10, 1514-1518.
15. Liliemark, J., Pettersson, B. & Juliusson, G. (1991) The relationship between plasma 2-chloro-2′-deoxyadenosine in humans: alternative routes of administration. Blood, 78, (Suppl. 1), 33a (A122).
16. MacKenzie, M.R. & Fudenberg, H.H. (1972) Macroglobulinemia: an analysis of forty patients. Blood, 39, 874-889.
17. Ohno, R., Kodera, Y., Ogura, M., Murax, T., Emi, N., Okumura, M., Morishita, Y., Nagura, E., Minami, S. & Morishima, Y. (1985) Treatment of plasma cell neoplasm with recombinant leukocyte A interferon and human lymphoblastoid interferon. Cancer Chemotherapy and Pharmacology, 14, 34-37.
18. Piro, L.D. (1996) Cladribine in the treatment of low-grade non-Hodgkin's lymphoma. Seminars in Hematology, 13, 2476.
19. Pott-Hoeck, C. & Hiddemann, W. (1995) Purine analogs in the treatment of low-grade lymphomas and chronic lymphocytic leukemias. Annals of Oncology, 6, 421-433.
20. Quesada, J.R., Alexanian, R., Kurzrock, R., Barlogie, B., Saks, S. & Gutterman, J.U. (1988) Recombinant interferon gamma in hairy cell leukemia, multiple myeloma, and Waldenström's macroglobulinemia. American Journal of Hematology, 29, 1-4.
21. Riddell, S., Johnston, J.B., Rayner, H.L. & Israels, L.G. (1986) Response to Waldenström's macroglobulinemia to pentostatin (2′-deoxycoformycin). Cancer Treatment Reports, 70, 546-548.
22. Sonderegger, T.A., Betticher, D.C., Egger, T., Von Rohr, A., Cerny, T. & Lauterburg, B. (1996) 2-Chlorodeoxyadenosine (2-CDA), pharmacokinetic comparison of continuous intravenous (iv) and subcutaneous bolus (sc) application. Annals of Oncology, 7, (Suppl. 3), 186 (A693).
23. Tallman, M.S. & Hakimian, D. (1995) Purine nucleoside analogs: emerging roles in indolent lymphoproliferative disorders. Blood, 86, 2463-2474.
24. World Health Organization (1979) Handbook for Reporting Results of Cancer Treatment. W.H.O. offset publication no. 48. Geneva, Switzerland.
25. Zinzani, P.L., Gherlinzoni, F., Bendandi, M., Zaccaria, A., Aitini, E., Salvucci, M. & Tura, S. (1995) Fludarabine treatment in resistant Waldenström's macroglobulinemia. European Journal of Haematology, 54, 120-123.